ESMO: Lilly's Retevmo drives major benefits in lung, thyroid cancers as Roche bows out of competition
Fierce Pharma
OCTOBER 20, 2023
Eli Lilly is on a roll with its RET inhibitor Retevmo, with new trial results showing the drug can offer dramatic benefits in the treatment of certain lung and thyroid cancers. | Eli Lilly is on a roll with its RET inhibitor Retevmo, with new trial results showing the drug can offer dramatic benefits in the treatment of certain lung and thyroid cancers. (..)
286 
Let's personalize your content